Al-Sarraf, Metch, Kish, Ensley, Rinehart, Schuller, Coltman (1987) Platinum analogs in recurrent and advanced head and neck cancer: A Southwest Oncology Group and Wayne State University Study. Cancer Treat. Rep. 71:723-726.
Burton (1956) A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem. J. 62:315-323.
Calabresi, Parks (1985) Antiproliferative agents and drugs used for immunosuppression. The Pharmacological Basis of Therapeutics , A. Goodman Gilman, L.S. Goodman, T.W. Rall, F. Murad, Macmillan Co, New York; 1247-1306.
Calvert, Harland, Newell, Siddik, Harrap (1985) Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat. Rev. 12:51-57.
Canetta, Rozencweig, Carter (1985) Carboplatin: The clinical spectrum to date. Cancer Treat. Rev. 12:125-136.
Cuppage, Tate (1967) Repair of the nephron following injury with mercuric chloride. Amer. J. Pathol. 51:405-429.
Dobyan (1985) Long-term consequences of cisplatinum-induced renal injury: A structural and functional study. Anat. Rec. 212:239-245.
Dobyan, Hill, Lewis, Bulger (1981) Cyst formation in rat kidney induced by cis-platinum administration. Lab. Invest. 45:260-268.
Dobyan, Levi, Jacobs, Kosek, Weiner (1980) Mechanism of cis-platinum nephrotoxicity. II. Morphologic observations. J. Pharmacol. Exp. Ther. 213:551-556.
Eastman (1983) Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum (II) and cis-dichloro(ethylene-diamine) platinum (II). Biochemistry 22:3927-3933.
Goren, Forastière, Wright, Horowitz, Dodge, Kamen, Viar, Pratt (1987) Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity. Cancer Chemother. Pharmacol. 19:57-60.
Houghton, Hartnett, Campbell-Boswell, Porter, Bennett (1976) A light and electron microscopic analysis of gentamicin nephrotoxicity in rats. Amer. J. Pathol. 82:589-612.
Hutchison, Perez, Gandara, Lawrence, Kaysen (1988) Renal salt wasting in patients treated with cisplatin. Ann. Intern. Med. 108:21-25.
Jones, Chopra, Kaufman, Flamenbaum, Trump (1985) Cis-diamminedichloroplatinum (II)-induced acute renal failure in the rat. Correlation of structural and functional alterations. Lab. Invest. 52:363-374.
Knox, Friedlos, Lydall, Roberts (1986) Mechanism of cytotoxicity of anticancer platinum drugs: Evidence that cis-diamminedichloroplatinum (II) and cis-diammine-(1,1-cyclobutanedicarboxylato)-platinum (II) differ only in the kinetics of their interaction with DNA. Cancer Res. 46:1972-1979.
Laurent, Erickson, Sharkey, Kohn (1981) DNA crosslinking and cytotoxicity induced by cis-diamminedichloroplatinum (II) in normal, SV-40 transformed and tumor human cell lines. Cancer Res. 41:3347-3351.
Laurent, Maldague, Carlier, Tulkens (1983) Increased DNA synthesis in vivo after administration of low doses of gentamicin to rats. Antimicrob. Agents Chemother. 24:586-593.
Laurent, Yernaux, Nonclercq, Toubeau, Maldague, Tulkens, Heuson-Stiennon (1988) Tissue injury and proliferative response induced in rat kidney by cis-diamminedichloroplatinum (II). Virchows Arch. B 55:129-145.
Litterst, Weiss (1987) Clinical and experimental nephrotoxicity of cancer chemotherapeutic agents. Nephrotoxicity in the Experimental and Clinical Situation , P.H. Back, E.A. Lock, Martinus Nijhoff, Dordrecht; 771-816.
Loehrer, Einhorn (1984) Diagnosis and treatment. Drugs five years later. Cisplatin. Ann. Intern. Med. 100:704-713.
Logothetis, Samuels, Ogden, Dexeus, Chong (1987) Cyclophosphamide and sequential cisplatin for advanced seminoma: Long-term followup in 52 patients. J. Urol. 138:789-794.
Magil, Mavichak, Wong, Quamme, Dirks, Sutton (1986) Long-term morphological and biochemical observations in cisplatin-induced hypomagnesemia in rats. Nephron 43:223-230.
Mavichak, Wong, Quamme, Magil, Sutton, Dirks (1985) Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats. Kidney Int. 28:914-921.
Micetich, Barnes, Erickson (1985) A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino) (1,1-cyclobutanedicarboxylato)-platinum (II) and cis-diamminedichloroplatinum (II) on L 1210 cells. Cancer Res. 45:4043-4047.
Mulder, Sleijfer, De Vries, Uges, Mulder (1988) Renal dysfunction following high-dose carboplatin treatment. J. Cancer Res. Clin. Oncol. 114:212-214.
Munro, Fleck (1966) The determination of nucleic acids. Methods Biochem. Anal. 14:113-176.
Nonclercq, Toubeau, Laurent, Maldague, Tulkens, Heuson-Stiennon (1988) Light and electron microscopic characterization of the proliferative response induced by tobramycin in rat kidney cortex. Expt. Mol. Pathol. 48:335-352.
Prestayko (1981) Cisplatin and analogues: A new class of anticancer drugs. “Cancer and Chemotherapy,” Vol. III, “Antineoplastic Agents” , S.T. Crooke, A.W. Prestayko, Academic Press, New York; 133-154.
Safirstein, Winston, Moel, Dikman, Guttenplan (1987) Cisplatin nephrotoxicity: Insights into mechanisms. Int. J. Androl. 10:325-346.
Short, Burnett, Cox, Bus, Swenberg (1987) Site-specific renal cytotoxicity and cell proliferation in male rats exposed to petroleum hydrocarbons. Lab. Invest. 57:564-577.
Siddik, Newell, Boxall, Harrap (1987) The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem. Pharmacol. 36:1925-1932.
Siddik, Newell, Jones, Boxall Proc. Amer. Assoc. Cancer Res. 1982, 23:168.
Toubeau, Laurent, Carlier, Abid, Maldague, Heuson-Stiennon, Tulkens (1986) Tissue repair in rat kidney cortex following short treatment with aminoglycosides at low doses: A comparative biochemical and morphometric study. Lab. Invest. 54:385-393.
Tulkens (1986) Experimental studies on nephrotoxicity of aminoglycosides at low doses—Mechanisms and perspectives. Amer. J. Med. 80:105-114.
Vogelzang, Torkelson, Kennedy (1985) Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 56:2765-2770.
Wiltshaw, Evans, Jones, Baker, Calvert (1983) JM-8, successor to cisplatin in advanced ovarian carcinoma?. Lancet 1:587.
